50% Off! Beat the market in 2025 with InvestingProCLAIM SALE

Ananda Developments transitions to Ananda Pharma plc

Published 12/20/2024, 02:04 AM

LONDON - Ananda, a company operating in the cannabinoid therapy sector, announced today that it has officially rebranded to ANANDA PHARMA plc. The company, traded on the AQUIS Stock Exchange under the ticker ANA, specializes in developing treatments for complex conditions using cannabinoids.

The name change is set to take effect on the AQUIS exchange at 8:00 a.m. on December 23, 2024. Despite the rebranding, the company's ticker 'ANA' and financial identifiers, including its ISIN (GB00BDQPXQ60) and SEDOL (BDQPXQ6), will remain the same. The rebranding also includes a new website address, www.anandapharma.co.uk, and an update to the company's logo and branding.

Melissa Sturgess, the CEO of Ananda, stated that the name change underscores the company's dedication to advancing licensed cannabinoid medicines to patients. She emphasized the company's strategy to focus on the biopharmaceutical drug development pathway as a means to support patients and provide shareholder value.

Existing shareholders are advised that the change of name will not affect their shareholdings. Current share certificates are still valid and should be retained. Any future share certificates issued will display the new name of the company, ANANDA PHARMA plc.

The company's decision to adopt a new name and branding is part of its strategic initiative to better align with its core business and long-term objectives in the biopharmaceutical industry. This announcement is based on a press release statement issued by the company.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.